Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
BMY.RT was delisted on the 31st of December, 2020.
2 hedge funds and large institutions have $5.52M invested in Bristol-Myers Squibb Company Contingent Value Rights in 2022 Q4 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less capital invested
Capital invested by funds: $5.52M → $5.52M (-$398)
33% less funds holding
Funds holding: 3 → 2 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
BMY.RT Hedge Fund Activity: Q4 2022 in Review
2 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) for Q4 2022, worth a combined $5.52M — down 0.01% from $5.52M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of BMY.RT and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
- 2 institutional investors held Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) as of Q4 2022, down from 3 in Q3 2022.
- Funds reported $5.52M of Bristol-Myers Squibb Company Contingent Value Rights stock for Q4 2022, down 0.01% quarter-over-quarter.
- 0 funds opened new Bristol-Myers Squibb Company Contingent Value Rights positions in Q4 2022 and 1 closed out, a net change of -1 holder.
Based on aggregated 13F filings for Q4 2022.